KR KRSNAA
Krsnaa Diagnostics Q3 2026
KRKRSNAA

Krsnaa Diagnostics Q3 FY26 results (Oct–Dec 2025) and concall

Healthcare · Concall AI · Call held 6 Feb 2026

Management summary

  • Krsnaa Diagnostics reported a seasonally softer Q3 FY26 with revenue of ₹181.2 crores (up 4% YoY) and EBITDA of ₹47.4 crores (26% margin).
  • The quarter saw significant recovery of over ₹130 crores in government receivables, strengthening cash flows.
  • Retail segment continued its strong growth, expanding nearly 8x YoY.
  • Management highlighted temporary operational pauses and expansion costs as factors impacting current quarter margins, but expressed confidence in long-term growth and profitability.

Source: Inve concall analysis and management guidance record.

Highlights

  • Revenue from operations stood at ₹181.2 crores, representing approx. 4% YoY growth.

  • EBITDA for Q3 FY26 registered at ₹47.4 crores, translating into a 26% margin.

  • Recovered over ₹130 crores in long-pending government receivables, materially strengthening cash position.

  • Retail revenue grew by nearly 8x YoY, contributing approximately 8% to the overall group's revenue in 9MFY26.

What they filed

Q3 FY26: revenue down 133.3%, net profit down 27.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue9 10 8 2 -3 −133%
EBITDA48 53 50 58 48 +0%
Net profit22 21 20 23 16 −27%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Rajasthan Project Annualized Revenue Revenue · by end of FY27 · High confidence ₹200 crores
  • Apulki Hospital Mature Revenue Revenue · within 2-3 years · Medium confidence ₹20 crores

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Reasons for muted QoQ numbers and RPL breakeven status Direct
While yes, what you have shared is correct that year-on-year, it has a robust growth, quarter-on-quarter, it's a little muted. And that's mainly because of the series of festivities and the seasonality. Rest, all the levers are very well in place. And despite so much so seasonali

Clarifies the impact of seasonality and operational pauses on Q3 performance and reaffirms the breakeven target for the Rajasthan Pathology Lab (RPL) business.

Asked by Bala Murli Krishna

New order wins and pipeline for growth Partial
In terms of the order book or PPP projects in pipeline, there are a couple of projects that we are chasing. Two things. One is we have also been selective about the PPP project that we want to undertake given the kind of maturity and experience Krsnaa has. And also, considering R

Indicates a selective approach to new PPP tenders, focusing on deliverability and maturity, with a couple of projects in the pipeline, but no specific new major wins announced.

Asked by Bala Murli Krishna

Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 5 watchlist triggers for Q4 FY26
  • +3 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image